Immuno-PET imaging using 89Zr labeled PD-L1 antibody in non-small cell lung cancer Xenograft

Conclusions 89Zr-Df-KN035 demonstrates promise for use as an immuno-PET agent to image tumor PD-L1 expression in living system, which warrants further selection of patients with NSCLC performing anti-PD-L1 antibody therapy.

Source: Journal of Nuclear Medicine - May 23, 2016 Category: Nuclear Medicine Authors: Li, D., Zhu, X.-H. Tags: Preclinical Probes for Oncology-1 Source Type: research